Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: Results from an aborted randomised trial

International Journal of Psychiatry in Clinical Practice

Volumn 15, Issue 2, 2011, Pages 128-134

  Boonstra, Geartsje ^a,c   Burger, Huibert ^a,b   Grobbee, Diederick E ^c   Kahn, René S ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

antipsychotics; First episode; pyschopharmacology; schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SCHIZOPHRENIA;

EID: 79955753989     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2010.534801     Document Type: Article

References (27)

1. Davis JM, Janicak PG, Singla A, Sharma RP. Maintenance antipsychotic medication. In: Barnes T, editor. Antipsychotic drugs and their side-effects. Neuroscience perspectives. London: Academic Press Limited; 1993. p 183.
2. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52(3):173-88.
3. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158(11):1835-42. (Pubitemid 33054776)
4. Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE. The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull 1992;18(2):185-207.
5. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998;24(1):75-85. (Pubitemid 28128490)
6. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120-7. (Pubitemid 16158512)
7. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998;32(3-4):243-50. (Pubitemid 28408287)
8. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982; 39(1):70-3. (Pubitemid 12163378)
9. McCreadie RG, Wiles D, Grant S, Crockett GT, Mahmood Z, Livingston MG, et al. The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand 1989;80(6):597-602. (Pubitemid 20046946)
10. Lehman AF, Lieberman JA, Dixon LB, McGlashan MPHT, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 2004;161(2 Suppl):1-184.
11. First MB, Gibbon M, Spitzer RL, Williams JB, editors. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Version (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261-76. (Pubitemid 18039085)
13. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23(1):99-110.
14. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berlin) 2006;189(2):259-66. (Pubitemid 44691547)
15. Carpenter WT Jr, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147(9):1138-48. (Pubitemid 20275365)
16. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Twoyear relapse rates. Arch Gen Psychiatry 1974;31(5):603-8.
17. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48(12):1571-7. (Pubitemid 27512385)
18. Engelhardt DM, Rosen B, Freedman N, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization-a reevaluation. Arch Gen Psychiatry 1967;16(1):98-101.
19. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000;42(3):241-7. (Pubitemid 30216535)
20. Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(Suppl 12):5-19.
21. van Loenen AC, de Boer JE, Beckeringh JJ, Danz M, van ' t Hof AJ, Huppes W, et al. Pharmacotherapeutical compass. In: van Loenen AC, de Boer JE, editors. Utrecht: Commissie Farmaceutische Hulp van het College voor zorgverzekeringen. Pharmacotherapeutical Compass; 2009.
22. Pocock SJ. The Size of a clinical trial. In: Pocock SJ, editor. Clinical trials: A practical approach. Chicester: John Wiley & Sons Ltd; 1983. p 129.
23. Kuipers E, Kendall T. Schizophrenia (update). In: Antoniou J, Barnes T, Bhui K, Bird V, Brabban A, Flanagan E et al., editors. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). London: National Institute for Health and Clinical Excellence; 2009.
24. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007;68(5): 654-61. (Pubitemid 46841847)
25. Iancu I, Dannon PN, Ziv R, Lepkifker E. A follow-up study of patients with DSM-IV schizophreniform disorder. Can J Psychiatry 2002;47(1):56-60. (Pubitemid 34298250)
26. Jager M, Bottlender R, Strauss A, Moller HJ. Fifteen-year follow-up of ICD-10 schizoaffective disorders compared with schizophrenia and affective disorders. Acta Psychiatr Scand 2004;109(1):30-7. (Pubitemid 38161098)
27. Boonstra N, Wunderink L, de Wit PH, Noorthoorn E, Wiersma D. [The administrative incidence of non-affective psychoses in Friesland and Twente]. Tijdschr Psychiatr 2008;50(10):637-43.